BriaCell to present clinical biomarker data of Phase 3 Bria-IMT study

BriaCell (BCTX) Therapeutics will be presenting clinical biomarker data of its ongoing pivotal Phase 3 study of Bria-IMT plus an immune check point inhibitor in metastatic breast cancer at its poster presentation at the European Society for Medical Oncology Congress 2025 Annual Meeting taking place October 17 – 21 in Berlin, Germany. In BriaCell’s pivotal Phase 3 study of Bria-IMT plus an immune check point inhibitor in metastatic breast cancer, patients are randomized 1:1:1 to Bria-IMT + CPI, Physician’s Choice, or Bria-IMT monotherapy. As of the time of the abstract submission, data in 68 evaluable patients, with a median of 6 prior lines of treatment, was available. Additional data will be presented at the ESMO conference. Clinical efficacy data: Treatment arm agnostic biomarker positive subgroups showed significant improvement in progression free survival in patients who developed an immune response to Bria-IMT. Tolerability profile: Bria-IMT was well tolerated with no treatment-related discontinuations due to adverse events. Most common AEs include fatigue 22.8%, anemia 22.8%, and nausea 21.5%.